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Valproic acid (VPA) is a short-chain fatty acid commonly used for treatment of neurological disorders. As
VPA can interfere with cellular lipid metabolism, its effect on the infection of cultured cells by viruses of seven
viral families relevant to human and animal health, including eight enveloped and four nonenveloped viruses,
was analyzed. VPA drastically inhibited multiplication of all the enveloped viruses tested, including the
zoonotic lymphocytic choriomeningitis virus and West Nile virus (WNV), while it did not affect infection by the
nonenveloped viruses assayed. VPA reduced vesicular stomatitis virus infection yield without causing a major
blockage of either viral RNA or protein synthesis. In contrast, VPA drastically abolished WNV RNA and
protein synthesis, indicating that this drug can interfere the viral cycle at different steps of enveloped virus
infection. Thus, VPA can contribute to an understanding of the crucial steps of viral maturation and to the
development of future strategies against infections associated with enveloped viruses.
Conventional antiviral agents can interfere successfully with
viral components but often lead to development of drug resis-
tance in virus populations evolving under selective pressures
(9, 14). One of the approaches to circumvent this limitation is
the identification of antivirals targeted against cellular func-
tions required for the virus to complete its viral cycle, thus
reducing the potential of viruses to escape from drug effects
(26, 35, 44). Indeed, some long-used drugs commonly admin-
istered by clinicians to treat human disorders, such as lithium
or statins, have been proposed as new antiviral agent candi-
dates (3, 18, 20) as part of drug repositioning (finding of new
applications to licensed drugs) in drug development. Massive
screenings have also revealed the potential antiviral effect of
multiple clinical compounds, supporting this kind of approach
(17).
Valproic acid ([VPA] 2-propylpentanoic acid) is a branched
short-chain fatty acid commonly used for treatment of neuro-
logical disorders (6, 52). The proposed cellular targets of VPA
are diverse, including (i) interruption of -amino butyric acid
(GABA) signaling, (ii) inhibition of histone deacetylases
(HDAC), (iii) modulation of sodium channel activity, (iv) in-
hibition of glycogen synthase kinase 3, and (v) disruption of
membrane lipid metabolism, including that of phosphatidyl-
inositol (48, 53, 54, 57, 59).
As intracellular parasites, many viruses hijack cellular mem-
branes from host cells for virus replication and/or virion as-
sembly, and alterations in the membrane lipid environment
can interfere with these processes (22, 43). This prompted us to
examine the effect of VPA on the infectivity of different viruses
relevant to human and animal health, such as the flaviviruses
West Nile virus (WNV) and Usutu virus (USUV), the arena-
virus lymphocytic choriomeningitis virus (LCMV), the rhab-
dovirus vesicular stomatitis virus (VSV), the togaviruses Sem-
liki forest virus (SFV) and Sindbis virus (SINV), the asfivirus
African swine fever virus (ASFV), the poxvirus vaccinia virus
(VACV), and the picornaviruses foot-and-mouth disease virus
(FMDV), encephalomyocarditis virus (EMCV), bovine en-
terovirus (BEV), and equine rhinitis A virus (ERAV). We
observed that VPA caused a drastic reduction of the yield of all
enveloped viruses (WNV, USUV, VSV, SFV, SINV, LCMV,
VACV, and ASFV) but did not affect the nonenveloped vi-
ruses FMDV, EMCV, BEV, and ERAV. We further analyzed
the effect of VPA on enveloped virus infections. For this pur-
pose, two viruses, VSV and WNV, whose infectious cycle are
well characterized (1, 5, 13, 19, 28, 30, 33, 36, 46) were used.
Our results indicate that VPA reduced the yield of these two
viruses by more than 7 orders of magnitude; however, while
both WNV RNA and protein synthesis were drastically abol-
ished, no major blockage of VSV RNA and protein synthesis
was observed, indicating that VPA can interfere at different
steps of enveloped virus infection. These results make VPA an
interesting drug for understanding the crucial steps of viral
maturation and for developing future strategies against infec-
tious diseases associated with enveloped viruses.
MATERIALS AND METHODS
Cells, viruses, antibodies, and reagents. BHK-21 cells (ATCC) and Vero cells
(ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco-BRL, Invitrogen, Carlsbad, CA) supplemented with 5% fetal calf serum
(FCS) (Sigma, St. Louis, MO), L-glutamine (2 mM), penicillin (100 U/ml), and
streptomycin (100 g/ml). Type C FMDV C-S8c1 (50), BEV (23), EMCV (47),
SFV and SINV (55), VSV Indiana (40), LCMV (37), and Western Reserve
VACV (4) viral stocks were grown in BHK-21 cells. USUV (7), WNV (10),
ERAV (32), and ASFV strain BA71V (15) stocks were amplified in Vero cells.
Antibodies against WNV E glycoprotein from Chemicon (Temecula, CA), acety-
lated histone H3 (AcH3) from Upstate (Lake Placid, NY), and tubulin (2) were
used. The remaining antibodies and stains used have been previously described
(38). Valproic acid sodium salt, VPA (Sigma), was directly dissolved in DMEM.
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The effect of VPA in cultured cells was analyzed by trypan blue exclusion (51).
Trichostatin A (TSA) (Cell Signaling Technology, Danvers, MA) was prepared
in ethanol as a 4 mM stock solution.
Infections and virus titrations. Confluent monolayers (grown in six-well
plates) of BHK-21 or Vero cells were extensively washed with DMEM and left
untreated or were pretreated with VPA for 10 min. Cells were infected with
the different viruses at the selected multiplicity of infection (MOI), defined as the
number of PFU/cell. After the first infection hour (or 1.5 h for LCMV) in the
presence or absence of VPA, the viral inoculum was removed, the cell monolayer
was washed twice with DMEM, and fresh medium containing 5% FCS and VPA
was added; this time point was considered 0 h postinfection (p.i.). Seven hours
(for FMDV, EMCV, BEV, VSV, SFV, SINV, and VACV) or 24 h (for ERAV,
LCMV, WNV, USUV, and ASFV) later infected plates were frozen. To test the
effect of the p.i. addition of VPA, the drug was added and maintained from 2.5 h
p.i. To analyze the effect of TSA, BHK-21 cells were left untreated or were
pretreated with 400 nM TSA for 16 h, as described by the manufacturer. At this
time, cells were infected with FMDV, VSV, SFV, SINV, LCMV, or VACV, as
described previously, and TSA was maintained throughout the infection period
(total TSA treatment of 24 h). For WNV, USUV, and ASFV, Vero cells were
treated at the time of infection with 400 nM TSA, and infections were allow to
proceed for 24 h. For virus titration, unless otherwise stated, infected plates were
subjected to three freeze-thaw cycles, and the total (intracellular and medium-
released) virus yield was determined by plaque assay in BHK-21 or Vero cells as
described previously (15, 47, 50). Briefly, after the first hour of infection, viral
inoculum was removed, and medium containing 0.5% agar, 1% FCS, and DEAE-
dextran (0.045 mg/ml) was added. For LCMV, after 1.5 h of infection, the viral
inoculum was removed, and medium containing 0.3% agar, 1% FCS, and DEAE-
dextran (0.045 mg/ml) was added. For WNV and USUV, after inoculum re-
moval, infections were allowed to proceed in semisolid medium containing 1%
low-melting-point agarose and 2% FCS. Plates were incubated at 37°C for 24 h
(FMDV, EMCV, and VSV), 48 h (BEV, ERAV, SFV, and SINV), 72 h (VACV,
WNV, and USUV) or 1 week (LCMV and ASFV). At this time point, cells were
fixed in 4% formaldehyde for 15 min at room temperature and stained with 3%
crystal violet in 2% formaldehyde.
Detection of viral RNA and proteins and concentration of viral particles. VSV
particles were sedimented from VSV-infected BHK-21 cell medium as described
previously (21). For VSV, total (intracellular and extracellular) RNA and extra-
cellular RNA were extracted using Tri-Reagent (Sigma). Samples were 10-fold
serially diluted in water, and VSV cDNA was synthesized and amplified by
reverse transcription-PCR (RT-PCR) (41). Glyceraldehyde-3-phosphate-dehy-
drogenase (G3PDH) RNA amplification was used as an internal control for
cellular RNA content (16). PCR products were analyzed by agarose gel electro-
phoresis (2%) and ethidium bromide staining. For WNV, viral RNA was ex-
tracted using a NucleoSpin viral RNA isolation kit (Macherey-Nagel, Du¨ren,
Germany) and quantified by quantitative RT-PCR as genomic equivalents to the
number of PFU/ml by comparison with RNA extracted from titrated samples
(27). For VSV protein detection by dot blot, infection medium samples were
loaded onto a nitrocellulose membrane, which was blocked, incubated with a
guinea pig hyperimmune serum against VSV Indiana and then with horseradish-
peroxidase (HRP)-labeled goat anti-guinea pig IgG, and subsequently developed
using an ECL kit (Amersham). These antibodies were also used for Western blot
detection (38).
TEM and immunofluorescence. Transmission electron microscopy (TEM) and
immunofluorescence were performed as previously described (38). To determine
the number of infected cells in immunofluorescence assays, three coverslips per
time point were examined, and at least 500 cells were counted. The number of
viral particles attached to the cell surface/nm was scored using the NeuronJ
plug-in (39) of ImageJ software (http://rsbweb.nih.gov/ij/). For negative staining,
VSV virions were concentrated from infection medium (21) and fixed with 1%
glutaraldehyde. Samples were adsorbed for 3 min to copper grids coated with
collodion-carbon and ionized. Grids were negatively stained with 2% uranyl
acetate and air dried.
Data analysis. One-way analysis of variance was performed with the statistical
package SPSS, version 17.0 (SPSS, Inc., Chicago, IL) for Windows. For multiple
comparisons, Bonferroni’s correction was applied. Data are presented as
means standard deviations. Differences were considered statistically significant
at a P value of 0.05.
RESULTS
Effect of VPA on viral infection. We first evaluated the via-
bility of BHK-21 and Vero cells treated with the drug (Fig.
1A). The 50% toxic concentration (TC50) was 244 and 280 mM
after 8 h of treatment and 178 and 154 mM after 25 h of
treatment for BHK-21 and Vero cells, respectively. Microtu-
bules, actin microfilaments, the Golgi complex, and the endo-
plasmic reticulum architecture were not altered by VPA treat-
ment (Fig. 1B). Next, the effect of treatment with VPA on the
viral yield of four nonenveloped and eight enveloped viruses
was analyzed (Fig. 2). No statistically significant reduction in
the virus yield postinfection was found for any of the nonen-
veloped viruses. Conversely, complete inhibition, ranging from
6 to 10 orders of magnitude, was observed in the virus yield
from infections with the enveloped viruses when VPA was
added before infection and maintained throughout the assay,
except for VACV, whose yield, albeit reduced by about 4 logs,
was not completely inhibited. For the viruses tested on the two
cell lines used in this study, the inhibitions observed were
similar, regardless of whether VPA was added before infection
or postinfection (p.i.), with the only exception being SINV
infection of BHK-21 cells, in which p.i. addition of VPA re-
sulted in a reduction of viral titer by 4 orders of magnitude
FIG. 1. Effect of VPA on cell viability. (A) BHK-21 and Vero cells
were incubated for 8 or 25 h in the presence of increasing concentra-
tions of VPA and then analyzed for cell viability by trypan blue assay.
(B) BHK-21 cells, either untreated or treated for 8 h with 50 mM VPA,
were fixed and processed for immunofluorescence using antibodies
against marker proteins from different cell structures. DAPI (4,6-
diamidino-2-phenylindole) was used to stain cell nuclei (blue). Scale
bar, 20 m.
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instead of the complete suppression (over 7 orders of magni-
tude) observed on Vero cells. Overall, these results indicate
that VPA affects mainly postentry steps in the multiplication of
the enveloped viruses analyzed in the present study.
Inhibition of histone deacetylases does not affect viral in-
fection. Inhibition of histone deacetylases is one of the effects
of VPA on cells (54, 57), which has been proposed to have an
antiviral effect on latent infections (11, 29, 31, 61). To address
the implication of this mechanism on the inhibition observed in
this study, the effect of TSA—another HDAC inhibitor
(8)—on the infection of FMDV, SFV, SINV, VSV, VACV,
LCMV, ASFV, WNV, and USUV was tested. As expected,
treatment with TSA resulted in an increase in the levels of the
acetylated histone AcH3 (Fig. 3A). However, TSA did not
significantly affect infection of the viruses tested (Fig. 3B),
supporting the idea that this mechanism does not play a major
role on the antiviral effect exerted by VPA.
VPA inhibits viral infection in a dose-dependent manner
without drastically inactivating viral particles. From the anal-
ysis of the effect of VPA on viral growth, 50% inhibitory con-
centrations (IC50s) of 0.6 and 0.25 mM were determined for
VSV and WNV, respectively (Fig. 4A and C). To asses a
possible direct effect of VPA on the infectivity of viral particles,
as described for other antiviral drugs directed against envel-
oped viruses (58), equal numbers of PFU were treated with
VPA, and the infectivity levels of the samples were determined
by plaque assay after incubation at 37°C for up to 8 h (Fig. 4B
and D). While no statistically significant differences were found
in the VSV titers observed in control and VPA-treated samples
(Fig. 4B), a reduction of 2 orders of magnitude was observed
for WNV (Fig. 4D). These results indicate that VPA, although
differentially affecting VSV and WNV viral particles, does not
produce a major effect on the infectivity of the viral particles,
and they suggest that VPA inhibition of viral yield is mainly
mediated by intracellular alterations of infected cells.
Effect of VPA on viral replication. A concentration of 50 mM
VPA that completely abolished viral production (Fig. 2) was
used to perform a time course analysis of VSV and WNV virus
production, protein expression, and RNA synthesis (Fig. 5). As
expected, while infectious virus was recovered shortly after
infection in control cells, no infectious virus was detected in
VPA-treated cells infected with either VSV or WNV up to 8.5
and 24 h p.i., respectively (Fig. 5A and D). Upon WNV infec-
tion, fluorescence against WNV E protein and viral RNA, the
FIG. 2. Effect of VPA on virus yield. BHK-21 or Vero cell monolayers, either untreated or treated with 50 mM VPA, were infected with the
indicated viruses (MOI of 0.5 PFU/cell), as described in Materials and Methods. Preinfection analysis corresponds to infections performed in the
presence of drug before infection (pretreatment) and throughout the infection time. In the case of postinfection analyses, VPA was added at 2.5 h
pi and maintained throughout the infection time. Statistically significant differences between control and VPA-treated cells are indicated by an
asterisk (P  0.05).
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latter being amplified in control cells from 16 h p.i, was not
detected in VPA-treated cells at any time point (Fig. 5B and
C). In contrast, a reduced percentage of cells positive for
fluorescence against the VSV G glycoprotein (VSV-G) was
found in VSV-infected cells treated with VPA, and only con-
trol cells, not VPA-treated cells, showed a marked increase in
the percentage of fluorescent cells from 4.5 h p.i., a time at
which untreated cells were actively producing new viruses (Fig.
5D and E). These results suggest that VSV progeny from
control cells but not from VPA-treated cells was released to
the infection medium and infected neighbor cells. Likewise, in
total RNA (intracellular and extracellular) from control VSV-
infected cells, viral RNA was already detected at 4.5 h p.i while
in VPA-treated VSV-infected cells, viral RNA detection was
delayed until 6.5 h. p.i., and the levels were lower than those
observed in nontreated control cells (Fig. 5F). On the other
hand, no differences were found in the intracellular distribu-
tion pattern of VSV-G protein between control cells and those
treated with VPA that were positive for VSV-G staining (Fig.
5G). VSV-G protein was observed perinuclearly at 2.5 h p.i.,
indicating its accumulation in the Golgi complex; at later in-
fection stages (6.5 h p.i.) this protein was observed at the cell
periphery, where newly synthesized virions acquire their enve-
lope. When the VSV proteins were detected in infected cells by
Western blotting using a polyclonal VSV serum, a reduction of
about 10-fold was noticed in the amount of protein N found in
VPA-treated cells relative to that of control infected cells (Fig.
5H). Whether the differences observed in VSV RNA and pro-
tein detection are due to a reduction in their synthesis in
VPA-treated cells and/or to the increasing number of infected
control cells remains to be determined. Thus, even though no
infective viruses are released from either WNV- or VSV-in-
fected cells, VPA intracellular effects on the infectivity of both
FIG. 4. VPA inhibits VSV and WNV infection in a dose-depen-
dent manner, but VPA treatment does not inactivates VSV particles
even though it reduces the infectivity of WNV particles.
(A) BHK-21 cells were infected with VSV (MOI of 0.5 PFU/cell) in
the presence of different concentrations of VPA, and the total virus
yield was determined by plaque assay. Dotted lines correspond to
IC50s. (B) VSV particles were incubated with 50 mM VPA at 37°C
for 1 h or 8 h, and virus titer was determined by plaque assay.
(C) Vero cells were infected with WNV as described in panel A.
Dotted lines correspond to IC50s. (D) WNV particles were incu-
bated with VPA as described in panel B, and infectivity was deter-
mined by plaque assay. Statistically significant differences between con-
trol and VPA-treated cells are indicated by an asterisk (P  0.05).
FIG. 3. Inhibition of histone deacetylases does not affect viral infection. (A) Western blot analysis of acetylated histone H3 (AcH3) in
BHK-21 and Vero cells after TSA treatment. Results obtained with an anti--tubulin antibody are shown as a control for protein loading.
(B) BHK-21 or Vero cell monolayers, either untreated or treated with 400 nM TSA, were infected with FMDV, SFV, SINV, VSV, LCMV,
VACV, ASFV, WNV, or USUV (MOI of 0.5 PFU/cell). Virus yield was determined by plaque assay as described in Materials and Methods.
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viruses seem to differ. Taken together, these results indicate
that while in some viruses, such as WNV, VPA can produce a
drastic blockage of replication and translation of viral RNA, in
other viruses (VSV) this reduction is less severe.
Effect of VPA on VSV morphogenesis. Since in VPA-treated
cells infected by VSV, G protein was observed at the cell
periphery, where newly synthesized virions acquire their enve-
lope, we further analyzed whether VPA treatment interfered
with viral particle formation and egress. To this purpose,
BHK-21 cells, treated or not with this drug, were infected with
VSV, fixed, and processed for TEM. In both cases, similar
images corresponding to newly assembled VSV particles (60)
could be observed (Fig. 6A). When the number of viral parti-
cles/m of membrane was quantified, no significant differences
between control and VPA-treated cells were found (Table 1).
Similarly, no significant differences in the lengths and diame-
ters of the budding VSV particles were found between VPA-
treated and untreated infected cells, indicating that VPA does
FIG. 5. Effect of VPA on VSV and WNV infection. (A) Vero cells, either untreated or treated with 50 mM VPA, were infected with WNV
(MOI of 0.5 PFU/cell), and the virus titer in the extracellular medium was determined by plaque assay. (B) Cells infected as described in panel
A were fixed at different times p.i. and processed for immunofluorescence using a MAb against WNV-E glycoprotein. For each time point, the
percentage of fluorescent cells (infected cells) is shown. (C) Total viral RNA (intracellular and extracellular) from samples infected with WNV as
described in panel A was extracted at different times p.i. and amplified by quantitative RT-PCR as described in Materials and Methods.
(D) BHK-21 cells were infected with VSV, and the virus titer in the extracellular medium was determined as in panel A. (E) Cells infected with
VSV and processed as described in panel B using MAb I1 against VSV-G protein. (F) Detection of VSV RNA by RT-PCR. BHK-21 cell
monolayers were infected with VSV as in panel A. Total viral RNA was amplified by RT-PCR. G3PDH amplification was used as an internal
control for cellular RNA content. (G) Representative micrographs of VSV-G-positive cells infected and immunostained as described in panel E.
Scale bar, 20 m. (H) Detection of VSV proteins by Western blotting. BHK-21 cell monolayers were infected with VSV as in panel A. For each
time point, cells were lysed and processed for Western blotting using a guinea pig hyperimmune serum against VSV Indiana. The migration of the
band shown corresponded to that expected for VSV N protein. Results obtained with an anti--actin antibody are shown as a control for protein
loading.
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not cause a major blockage of intracellular VSV particle for-
mation. To analyze whether the de novo synthesized viral par-
ticles were actually released from VPA-treated cells, medium
from infected cultures, treated or not with VPA, was sedi-
mented under conditions used for VSV purification. In control
infections, bullet-shaped particles corresponding to VSV viri-
ons were observed by TEM in resuspended pellets (an average
of 31  9.2 particles/field in 20 random fields). None particles
of this type were found in the 20 random fields from VPA-
treated infected cells (Fig. 6A), suggesting that VPA treatment
could either block virion budding or alter VSV composition,
producing virions with a highly reduced stability in the infec-
tion medium and/or during the sedimentation process. As
shown in Fig. 6B, the latter possibility seems to be favored
since VSV RNA and proteins were detected in the extracellu-
lar medium of infection at levels only about 10-fold lower than
those found in control infected cells.
DISCUSSION
In this study we describe the antiviral effect of VPA on
different enveloped viruses causing human and veterinary dis-
eases, including important zoonoses such as those caused by
WNV and LCMV. Thus, cell culture infection of enveloped
viruses whose genomes consist of RNA of positive polarity
(WNV, USUV, SFV, and SINV), negative polarity (VSV), and
segmented and negative polarity (LCMV), as well as of DNA
(ASFV), was completely inhibited by VPA and that of the
DNA virus VACV was severely reduced. In general, the inhi-
bitions observed in BHK-21 and Vero cells were similar, sug-
gesting that the alterations produced by VPA that mediate its
antiviral activity affect common steps of mammalian cell me-
tabolism. However, the differential inhibition of SINV multi-
plication in BHK-21 and Vero cells when VPA was added after
virus entry indicates that the inhibition by VPA may also be
modulated by the cell type infected. In contrast, no significant
inhibitory effect was observed for nonenveloped viruses such as
FMDV, EMCV, BEV, and ERAV.
As noted in the introduction, different effects have been
described for VPA, which complicates the analysis and inter-
pretation of the inhibitions observed. One such effect is the
inhibition of histone deacetylases, which has been proposed to
favor depletion of cells latently infected with human immuno-
deficiency virus (29), human T-cell leukemia virus type-1 (31),
and Epstein-Barr virus (11, 61). The lack of effect of the drug
TSA, which inhibits deacetylation of histones, on the infections
of the viruses studied indicates that this mechanism does not
play a major role in the observed antiviral effect of VPA. On
the other hand, a number of studies have shown that VPA
affects the lipid composition of cellular membranes (48, 52, 53,
59). Viruses acquire their lipid envelope from membranes of
host cells. For instance, flaviviruses, such as WNV and USUV,
acquire their envelope from intracellular membranes such as
those from the endoplasmic reticulum (56), while in other
viruses, such as VSV and SFV, the lipid composition of the
FIG. 6. Effect of VPA on VSV particle morphogenesis. (A) BHK-21 cells, either untreated or treated with 50 mM VPA, were infected with
VSV (MOI of 70 PFU/cell). Cells were fixed and processed for TEM at 7 h p.i. (left panels). VSV particles released to infection medium were
concentrated and processed for TEM (right panels). Scale bar, 200 nm. (B) VSV RNA amplification by RT-PCR and dot blot detection of VSV
proteins in extracellular medium of infected cells described in panel A.
TABLE 1. Effect of VPA treatment on the frequency and size of VSV budding particles in infected cells
Parameter
Value for the group
P
Control cells VPA-treated cells
Frequency of VSV buddinga 3.67  103  0.0136 4.65  103  0.0178 0.826
Avg particle size (nm)b
Length 160.61  35.57 144.61  38.00 0.088
Diam 63.01  10.50 63.29  8.46 0.394
a Average number of budding viral particles/m of cell surface (number of cell surfaces scored, 29).
b Average size of budding VSV particles was determined by measuring 57 particles from control cells and 24 particles from VPA-treated cells.
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virus particles strongly resembles that of the plasma membrane
of the cells used for virus growth (24). Therefore, the inhibitory
effect of VPA on enveloped virus multiplication described here
could be due to alterations in cellular membrane composition
that would result in impairment of infectious particle produc-
tion. Indeed, targeting plasma membrane anionic phospholip-
ids has been revealed as a promising new antiviral strategy
(49). Our results indicate that VPA completely blocks WNV
RNA and protein synthesis; whether this effect is associated
with alterations of endomembranes that could impair viral
RNA translation and/or replication or other cell effects of VPA
remains to be determined. Conversely, VPA did not cause a
major blockage of VSV RNA and protein synthesis as cells
positive for VSV-G protein were detected in immunofluores-
cence studies (Fig. 5E and G), and only a limited (about 10-
fold) reduction was observed in the amount of viral RNA and
proteins in infected cells. In these experiments, the increase in
the percentage of VSV-positive cells noticed in control mono-
layers was not observed in cells treated with VPA (Fig. 5E),
indicating that in the latter no infectious particles are released
from initially infected cells. Since VSV and other enveloped
viral particles acquire their envelope from the plasma mem-
brane (34), VPA treatment could impair this process due to
alterations in the plasma membrane lipid composition (48, 53,
59). However, comparable frequencies of budding particles
similar in size and length to those observed in control cells
were found in VPA-treated cells, suggesting that VPA does not
severely impair VSV particle assembly. Nevertheless, when we
attempted to concentrate VSV virions from infected cells, virion-
like particles were not detected in purified supernatants from
VPA-treated cells. The detection of VSV RNA and viral pro-
teins in the extracellular medium of infection, at levels only
10-fold lower than those found in control infected cells, sug-
gests that, rather than blocking virion budding, VPA treatment
alters VSV composition so as to leave extracellular particles
with a highly reduced stability. Overall, our results indicate that
at least two different mechanisms are involved in the inhibition
exerted by VPA on VSV and WNV cell culture infection, and
they point out that further experiments are required to char-
acterize these mechanisms and to extend these studies to other
viruses inhibited by this drug.
The present results raise the possibility of the therapeutic
antiviral potential of VPA, a widely used drug for nervous
disorders, including chronic treatments. Although the use of a
known drug that affects the nervous system as an antiviral
would require determining possible side effects, it could also
favor inhibition of neurotropic viruses such as WNV. Indeed,
in animal models VPA concentration in plasma positively cor-
relates with that found in the brain (42, 45). VPA doses usually
administered to humans are dependent on the body mass, with
a therapeutic range for epilepsy treatment of 50 to 100 mg/liter
(about 0.3 to 0.6 mM) in plasma (12, 25). These plasma con-
centrations are very close to the IC50s determined in our work
for VSV and WNV (0.6 and 0.25, respectively), supporting a
potential antiviral effect in vivo. For hypothetical therapeutic
applications, VPA pharmacokinetics should also be consid-
ered. This drug is metabolized by linear kinetics and its half-
life (in adults receiving monotherapy) ranges between 12  6
and 15  2.5 h, although due to the relatively rapid decrease in
serum concentrations of VPA, periodic doses should be ad-
ministered (25). Experiments in animal models are now being
designed to assess whether VPA can interfere viral infection in
vivo.
In summary, VPA is a potent inhibitor of virus multiplica-
tion in cultured cells of the enveloped viruses analyzed here,
including viruses of the Flaviviridae and Arenaviridae families,
which comprise a number of important human pathogens re-
sponsible for diseases such as yellow fever, dengue fever, hep-
atitis C, and hemorrhagic fevers. Even if further studies with a
wider range of virus families are required to address the anti-
viral spectrum of VPA, our results indicate that VPA may help
shed light on the crucial steps of envelope virus maturation and
that it might be a potential candidate for development as an
antiviral drug either alone or as coadjuvant in combined ther-
apies.
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